Analyst Ratings For Intellia Therapeutics (NASDAQ:NTLA)
Today, JMP Securities initiated coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Mkt Outperform .
Some recent analyst ratings include
- 3/8/2018-JMP Securities initiated coverage with a Mkt Outperform rating.
- 12/18/2017-Oppenheimer Reiterated Rating of Hold.
- 9/27/2017-Wedbush Reiterated Rating of Ourperform.
Recent Insider Trading Activity For Intellia Therapeutics (NASDAQ:NTLA)
Intellia Therapeutics (NASDAQ:NTLA) has insider ownership of 12.80% and institutional ownership of 68.14%.
- On 1/29/2018 Caribou Biosciences, Inc., Major Shareholder, sold 550,645 with an average share price of $26.78 per share and the total transaction amounting to $14,746,273.10.
- On 12/12/2017 Institutes For Biomed Novartis, Major Shareholder, sold 1,523,000 with an average share price of $18.30 per share and the total transaction amounting to $27,870,900.00.
- On 12/8/2017 Nessan Bermingham, CEO, sold 336,783 with an average share price of $20.78 per share and the total transaction amounting to $6,998,350.74.
- On 12/6/2017 Nessan Bermingham, CEO, sold 111,500 with an average share price of $20.34 per share and the total transaction amounting to $2,267,910.00.
- On 7/11/2017 Venture Fund Ix L.P. Atlas, Major Shareholder, sold 150,000 with an average share price of $16.24 per share and the total transaction amounting to $2,436,000.00.
- On 3/10/2017 Jean Francois Formela, Director, sold 21,132 with an average share price of $13.91 per share and the total transaction amounting to $293,946.12.
- On 5/11/2016 Bros. Advisors Lp Baker, Insider, bought 200,000 with an average share price of $18.00 per share and the total transaction amounting to $3,600,000.00.
Recent Trading Activity for Intellia Therapeutics (NASDAQ:NTLA)
Shares of Intellia Therapeutics closed the previous trading session at 32.00 up +2.57 8.73% with 32.125 shares trading hands.